Emcure Expands Poviztra® Use for MASH After CDSCO Approval
MM Desk
21 July, 2026
Emcure Pharmaceuticals Limited has expanded the use of its co-marketed brand Poviztra® following the approval
Emcure Pharmaceuticals Limited has expanded the use of its co-marketed brand Poviztra® following the approval
Emcure Pharmaceuticals Limited (BSE: 544210 | NSE: EMCURE) has announced the acquisition of the remaining
Emcure Pharmaceuticals has announced a significant price reduction for its weight management therapy Poviztra® (semaglutide
Emcure Pharmaceuticals Ltd (BSE: 544210 | NSE: EMCURE) has announced the nationwide commercial rollout of
Arth by Emcure, a wellness brand that merges scientific innovation with nature, has launched a
Emcure Pharmaceuticals Ltd (BSE: 544210, NSE: EMCURE) announced its consolidated financial results for the quarter
Pune-based Emcure Pharmaceuticals has announced its consolidated financial results for the quarter ending June 30,
Emcure Pharmaceuticals has announced its consolidated financial results for the fourth quarter and full year
Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has
Tillomed Laboratories Limited, the European arm of Emcure Pharmaceuticals Ltd., has entered into an Asset